	U.S. Patent re required to respond to a collection	Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number. Complete if Known
Sebstitute for form 1449/PTO	Application Number	09/965,738
INFORMATION DISCLOSURE	Filing Date	Sept. 27, 2001
STATEMENT BY APPLICANT	First Named Inventor	O'Brien, Timothy J.
	Art Unit	1642
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Examiner Name	Nickol, Gary B.
Sheet 1 of 1	Attorney Docket Number	110.018US1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PR		Accession Number AA640072, GenBank nucleotide sequence database, Oct. 27, 1997.	
		,	

Examiner	/Peter Reddig/	Date	05/13/2006
Signature	, - 0001 dans	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

					Docket Number (Optional) 022438.43865		Application Number	965,738	
R	in g	RMATION DISCLOSURE	CITATION		Applicant(s) Timothy J. O'Brien			00,700	
(MAY 1	CUSTS Several sheets if necessary	<i>'')</i>	Filing Date 9/27/01		Group Art Unit	1642		
- K	On.	O GALDY!		S. PATENT	DOCUMENTS				
•EXAMINER INITIAL	REP	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE
PR	AA	6,335,194	1-1-2002	Bennett	et al.	435/375		2-2-2000	
	ВВ	6,451,602	9-17-2002	Popoff e	et al.	435/375		3-2-2000	o
PR				<u> </u>					
			U.S. PATEN	T APPLICA	TION PUBLICATIONS				
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE OPRIATE
					,				
						<u> </u>			
			FORE	IGN PATEN	NT DOCUMENTS				
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	Trans YES	slation NO
							1		
						1			
						 			
						 			
							+		
			OTHER I	DOCUMENT	TS (Including Author	Title, Date, F	Pertinent Pages, Et	ic.)	
EXAMINE	R	/Peter Reddig/	·		DATE CONSIDERED	05/2	6/2006		
EXAMINEI not conside	R: Initi red. In	ial if citation considered, whether o clude copy of this form with next c	or not citation is in communication to (conformant applicant	te with MPEP Section 609; D	raw line thro	ugh citation if not	in conform	ance and

			· <u>-</u>			ATTY DOCKET NO.		PPLICATION N	10.	
\(\sigma\)	P		ATION DISCLOSURE			022438.43867		09/9	65,738	
	INF					APPLICANT(S)				
/		-001	se several sheets if necess	ary)		O'Brien, et al.		2012 12-11		
NEC	0 5	Mine	ຮູ້			FILING DATE	i i	ROUP ART UN	111	
132			<u>}</u>	-		September 27, 20	01			
*EXAMINER	מי אינול	E MARTE	/	U.S	S. PATENT	DOCUMENTS				
*EXAMINER	1700		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT	€
INITIAL	ļ—	-						-	IF APPROPE	RIATE
										~ ~
								1.		
			•			•		1		
		1		U.S. PATEN	IT APPLIC	ATION PUBLICATIONS	 	•	.—	
*EXAMINER			DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT	
- 			-							
				FORE	IGN PATE	NT DOCUMENTS	<u> </u>	<u></u>	<u> </u>	
			DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS		LATION
PR	AA	wo	00/36107	06/22/00	World		C12N 15/12	C07K 14/47	YES	NO
PR	ВВ	0 28	8 082	10/26/88	Europe		C07K 15/14	C12P 21/00	1	
PR	СС	wo	02/092836	11/21/02	World		C12Q		1	ļ
		+						-		
	-	+			<u> </u>					<u> </u>
	L	۲.	OTHER DOCUME	NTS (Includin	a Author	, Title, Date, Pertinent I	Pages Ftc	<u> </u> 	l	L
				<u>`</u>		out the antigen, its structur				
PR		DD	IT.J. O'Brien, et al.			ol. 13, no. 4, pp. 188-195	c and its fan			
PR		EE	"Isolation and Character Identification as a Mucin Kenneth O. Lloyd, et al. Int. J. Cancer: 71, 842-8	-type Molecule'	an Cancer	Antigen CA125 Using a N	ew Monoclo	nal Antibody (\	VK-8):	
EXAMINE	R		/Peter Reddig/			DATE CONSIDERED	05/26/2	006		
*EXAMINE	R: Ini	tial if re	ference considered, whethe py of this form with next con	er or not citation is nmunication to ap	in conform	nance with MPEP 609; Draw	line through c	itation if not in o	onformance	and not

Form PTO-A820 (also form PTO-1449)

			Docket Number (Optional) 022438 43867	Application Number 09/965,738
OI PIN	FORM	ATION DISCLOSURE CITATION	022438.4380 / Applicant(s)	V7/703,100
	57	(Use several sheets if necessary)	O'Brien, et al.	
DEC 0 2 20	البر الله			The state of the s
	<u> </u>	The second secon		
TATALEY.	ART.			a la
	A	"Immunohistochemical Characterization of 22 Mio ISOBM TD-1 Workshop" M. Nap, et al. Tumor F	noclonal Antibodies against tr Jiol. 1996: 17: 325-331	he CA125 Antigen 2nd Report from the
PR	FF			!
	 	"Human Musin Cone MIICSR the 10.7-kh Large	Control Even Encodes Variou	Altarnate Subdamains Resulting in a
PR		Super-repeat"	Central Exon Encoded	
	PR IIImmunohistochemical Characterization of 22 ISOBM TD-1 Workshop" M. Nap, et al. Tume Super-repeat" Jean-Luc Desseyn, et al. The Journal of Biological Chemistry, Vol. 272, "Isolation of the Murine Nbr1 Gene Adjacent of Julie Chambers, et al. Genomics 38, 305-313 (1996) PR IIII NCBI Sequence Viewer PR IIII NCBI Sequence Viewer PR IIII Nolecular Cloning of the CA125 Ovarian Can Beatrice W. T. Yin, et al. The Journal of Biological Chemistry, Vol. 276, PR IIIII The CA125 Gene: An Extracellular Superstructure Timothy J. O'Brien, et al. Tumor Biol. 2001; 22: 348-366 Extracellular Superstructure Timothy J. O'Brien, et al. Tumor Biol. 2002; 23: 154-169 EXAMINER PR /Peter Reddig/	. 6, Issue of February 7, pp. 3	168-3178 (1997)	
	+	"Isolation of the Murine Nhr1 Gene Adjacent to the	he Murine Rroat Gene"	
		Julie Chambers, et al.	it iriui int ar the game	!
PR INFORMATION DISCLOSURE CITATION OCCUMENTS (Including Author, Title, Date, Perlinear Pager, Etc.) The CALSS and the Cale of the Cale of Ca	!			
	+-	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?d/	o=nucleotide&val=2566012	
	<u> </u>	"Nucleotide" Lee Helman, M.D., et al.		
PR	lu lu			·
	+		r Antigen"	
PR			. 29, Issue of July 20, pp. 2737	/1-27375 (2001)
***	,,		•	· · · · · · · · · · · · · · · · · · ·
PR	†	"The CA125 Gene: An Extracellular Superstructu	ire Dominated by Repeat Sequ	uences"
	 KK	Tumor Biol. 2001; 22: 348-366		!
				!
		Extracellular Superstructure"	of the Glycosylated N-Termi	nal Domain Doubles the Size of This
PR	ᄔ	Timothy J. O'Brien, et al.		!
	}			
				!
	<u> </u>			
				!
-				
				!
				1
	+			
				•
				!
 	┼			
I				1
I				!
EXAMINER			DATE CONSIDERED	
}		/Peter Reddig/	05	5/26/2006
•FYAMINED.	-leigh if	alertica considered substitut or not disting is in configur	Land Mark Control Control	
		citation considered, whether or not citation is in conforma copy of this form with next communication to applicant.	INCE WILD MYEY Section duy; Dra	aw line through citation if not in conformance and

TECH CENTER 1600/2900

Substitute for form 1449APTO	Complete if Known			
200201016 tot total 14424 10	Application Number	09/965,738		
INFORMATION DICCLOCUDE	Filing Date	September 27, 2001		
INFORMATION DISCLOSURE	First Named Inventor	O'Brien, Timothy J.		
STATEMENT BY APPLICANT	Group Art Unit	Unassigned		
	Examiner Name	Unassigned		
(use as many modes as (at escary)	Attorney Docket Number	40715-260477		
Sheet 1 of 3	Express Mail Certificate	EV 032 104 775 US		
MAR 1 1 2002 &				
A U.S. F	ATENT DOCUMENTS			

	E.	U.S. PA	TENT DOCUMENTS		
Cite No.1	U.S. Patential	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
 					
Ţ					
-					
	 				
<u> </u>					<u> </u>
+	 				
 	 				
<u> </u>					
	Cite No.1	Cite No.1 Number	U.S. Patent Scurrent Kind Code ²	No. (Notice of Apresia	No. Cited Document Cited Document MM-DD-YYYY MM-DD-YYYYY MM-DD-Y

				FOREIG	N PAT	ENT DOCUMEN	ITS_			
Examiner Initials*		For	eign Patent Do	cument						
	Cita No.'	Office ³	Number ⁴	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	יד
					ļ				· · · · · · · · · · · · · · · · · · ·	┼-
		 	_					 		+
		+ +								
	<u> </u>	- -			<u> </u>			 		+-
								 		+-
<u> </u>		++		<u> </u>	-			1		+-

Examiner Signature	/Peter Reddig/	Date Considered	05/26/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Potent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of 3

Соп	nplete if Known	\sim)
Application Number	09/965,738	OIPE
Filing Date	September 27, 20	0)
First Named Inventor	O'Brien, Timothy	<i>\\</i>
Group Art Unit	Unassigned	VAN 4 4 2002
Examiner Name	Unassigned	MAK I ZOOK
Attorney Docket Number	40715-260477	ध
		8
· · · · · · · · · · · · · · · · · · ·		MADEMARK

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
PR	1	BAST RC et al., A radioimmunoassy using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med. 309:883-887 (1983)	7
PR	2	BON GC et al., Serum tumer marker immunoassays in gynecologic oncology: Establishment of reference values, Am J Obstet. Gynecol. 174:107-114 (1996)	~
PR	3	CLEMONS-MILLER, A et al. Intrathecal Cytotoxic T-Cell Immunotherapy for Metastatic Leptomeningeal Melanoma. Clinical Cancer Research 7:917s-924s, March 2001 (Suppl.)	7
PR	4	DESSEYN JL et al., Human mucin gene MUC5B, the 10.7-kb large central exon encodes various alternate subdomains resulting in a super-repeat. Structural evidence for a 11p15.5 gene family, J Biol. Chem. 272(6):3168-3178 (1997)	7
PR	5	FENDRICK, JL et al. Characterization of CA 125 Synthesized by the Human Epithelial Amnion WISH Cell Line. <i>Tumor Biol</i> 1993; 14:310-318	-
PR	6	FENDRICK, JL et al. CA125 Phosphorylation Is Associated with Its Secretion from the WISH Human Amnion Cell Line. <i>Tumor Biol</i> 1997; 18:278-289	'
PR	7	FOON, KA et al., Are solid tumor anti-idotype vaccines ready for prime time?, Clinical Cancer Research 7:1112-1115 (2001)	•
PR	8	GENDLER SJ et al., Epithelial mucin genes, Annu. Rev. Physiol. 57:607-634 (1995)	,
PR	9	GUM Jr., JR, Mucin genes and the proteins they encode: Structure, diversity and regulation, Am J Respir. Cell Mol. Biol. 7:557-564 (1992)	Ţ.
PR	10	GUM JR, Human Mucin Glycoproteins: Varied Structures Predict Diverse Properties and Specific Functions. Biochemical Society Transactions. 23(4):795-799, 1995.	,
PR	11	HARDARDOTTIR H et al., Distribution of CA125 in embryonic tissue and adult derivatives of the fetal periderm, Am J Obstet. Gynecol. 163;6(1):1925-1931 (1990)	•
PR	12 KONISH Let al. Enidownal grouph factor anhances accretion of the assertion for		
PR	13	LLOYD KO et al., Synthesis and secretion of the ovarian cancer antigen CA125 by the human cancer cell line NIH: OVCAR-3, Tumor Biology 22, 77-82 (2001)	
PR	14	LLOYD KO et al., Isolation and characterization of ovarian cancer antigen CA125 using a new monoclonal antibody (VK-8): Identification as a ucin-type molecule, Int. J. Cancer, 71:842-850 (1997)	•
PR	15	MARSHALL E, DNA Sequencing: Genome teams adjust to shotgum marriage, Science 292:1982-1983 (2001)	7
PR	16	NAP M et al., Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2 nd report from the ISOBM TD-1 workshop, Tumor Biology 17:325-331 (1996)	,
PR	17	NUSTAD K et al., CA125 – epitopes and molecular size, Int. J of Biolog. Markers, 13(4)196-199 (1998)	7

+

Please type a plus sign (+) inside this box

P.E.

Under the Paperwork Reduction and 1995, no person

SUBSTITUTE for form 1449APTO

INFORMATION DISCLOSURE OF STATEMENT BY APPLICANT

(USO 23 Many shoots as necessary)

3 of 3

Sheet


Complete if Known				
Application Number	09/965,738			
Filing Date	September 27, 2001			
First Named Inventor	O'Brien, Timothy J.			
Group Art Unit	Unassigned			
Examiner Name	Unassigned			
Attorney Docket Number	40715-260477			

PR	18	NUSTAD K et al., Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: First report from the ISOBM TD-1 workshop <i>Tumor Biology</i> 17:196-219 (1996)	1			
PR	19	O'BRIEN, TJ et al. CA 125 Antigen in Human Amniotic Fluid and Fetal Membranes. Am J Obstet Gynecol 155:50-55 July, 1986	1			
PR O'BRIEN, TJ et al. New Monoclonal Antibodies Identify the Glycoprotein Carrying the CA 125 Epitope. Am J Obstet Gynecol 1991; 165-1857-64						
PR	21	O'BRIEN, TJ et al. More Than 15 Years of CA 125: What Is Known about the Antigen, Its Structure and Its Function. The International Journal of Biological Markers 13:188-195 (1998)				
PR	22	QUIRK, JR et al. CA 125 in Tissues and Amniotic Fluid During Pregnancy. Am J Obstet Gynecol 159:655-649 (1988)	~			
PR	23 SANTIN AD et al. Induction of Overign Tumor Specific CD8+ Createrie T					
PR	24	SANTIN, AD et al. In vitro Induction of Tumor-Specific Human Lymphocyte Antigen Class I-Restricted CD8+ Cytotoxic T Lymphocytes by Ovarian Tumor Antigen-Pulsed Autologous Dendritic Cells from Patients with Advanced Ovarian Cancer. Am J Obstet Gynecol 2000; 183:601-9	~			
PR	25	SHIGESMASA, K, et al. p21: a Monitor of p53 Dysfunction in Ovarian Neoplasia. International Journal of Gynecologic Cancer 7:296-303, 1997.	1			
PR	26	SHIGESMASA, K, et al. p16 Overexpression: A Potential Early Indicator of Transormation in Ovarian Carcinoma. J Soc Gynecol Invest 4:95-102, 1997.	~			
PR	27	VERMA M et al., Mucin genes: Structure, expression and regulation, Glycoconjugate J. 11:172-179 (1994)	1			
PR	27	WAGNER, U. et al. Immunological Responses to the Tumor-Associated Antigen CA125 in Patients with Advanced Ovarian Cancer Induced by the Murine Monoclonal Anti-Idiotype Vaccine ACA125. HYBRIDOMA 16:33-40 (1997)	1			
PR	29	WAGNER U et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment, Clin. Cancer Res. 7:1112-1115 (2001)	Y			
PR	30 WILLIAMS, SJ et al. MUC13, a Novel Human Cell Surface Mucin Expressed by					
PR	31	YIN TWT et al., Molecular cloning of the CA125 ovarian cancer antigen. Identification as a new mucin (MUC16), J Biol. Chem. 276:27371-27375 (2001)	1			
PR	32	ZURAWSKI VR et al., Tissue distribution and characteristics of the CA125 antigen, Cancer Rev. 11-12:102-118 (1998)	1			

Commenter of			
Examiner		Date	05/26/2007
0:	/Dotom Poddia/	Date	05/26/2006
Signature	/Peter Reddig/	Considered	1,,
		Considered	1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



OIPE				022438.43867 Application Number 09/965,738						
- 1		RMATEON DISCLOSURI	E CITATION ary)		Applicant(s) O'Brien, et al.					
FEB 0 2 2004				,	Filing Date Group Art Unit September 27, 2001					
Filing Date September 27, 2001 U.S. PATENT DOCUMENTS *EXAMINER REF DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE										
*EXAMINER	REF	DOCUMENT NUMBER	DATE	NAME CLASS SUBCLASS				FILING DATE		
PR	cc	10/715,066	11/17/03	O'Brien, et al.					IF APPROPRIATE 1/17/03	
PR	DD	10/475,117	10/16/03	O'Brien, et al.		<u> </u>	10/16/03			
		10/4/0,11/	10/10/03	J 27.0.		<u> </u>				
						<u> </u>			<u> </u>	
				 		<u> </u>				
									-	
			_							
	<u> </u>		 	FOREIG	N PATENT DOCUMENTS			<u> </u>		
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	S Translation YES NO		
								11.5	110	
						<u> </u>	<u> </u>			
			 		· · · · · · · · · · · · · · · · · · ·		+			
			·							
	L									
	<u> </u>			OTHER I	DOCUMENTS (Including .	Author, Title,	Date, Pertinent Po	iges, Etc.)		
·										
EXAMINE	R	/Peter Reddig/			DATE CONSIDERED	05/26/	2006	_		
EXAMINE	R: Initi red. In	al if citation considered, whether clude copy of this form with next	or not citation is in communication to	conforman applicant.	ce with MPEP Section 609; D	Praw line thro	ugh citation if no	in conform	ance and	

OIPE	<u> </u>		Docket Number (Optional) 022438.43867	Application Number 09/965,738
INE	OBA	ATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) O'Brien, et al.	
FEB 0 2 2	004 E		Filing Date September 27, 2001	Group Art Unit
EXAMINER	المحدا	OTHER DOCUMENTS (Including Author, Title		
A DE	· ·	O'Brien, et al. "The CA125 Gene: An Extracellular Superstructur	a Dominated by Raneat Sequences"	
PR	AA	"The CA125 Gene: An Extracellular Superstructur Tumor Biology, Vol. 22, 2001 pp. 348-366	e Dominated by Repeat Sequences	
PR	вв	Argueso, et al. "MUC16 Mucin is Expressed by the Human Ocular Invest Ophthalmol Vis Sci 2003 Jun:44(6):2487-95	Surface Epithelia and Carries the H	85 Carbohydrate Epitope"
				·
			·	
			·	
EXAMINER		/Peter Reddig/	DATE CONSIDERED 05/26/2006	
*EXAMINER: In not considered.	nitial if c	citation considered, whether or not citation is in conforman copy of this form with next communication to applicant.	ce with MPEP Section 609; Draw line thr	ough citation if not in conformance and